Loading clinical trials...

Immune Responses to Dengue and Sepsis | Clinical Trials | Clareo Health

RECRUITING

Immune Responses to Dengue and Sepsis

Evaluating Immune Responses to Dengue and Sepsis in Hospitalized Patients in Cambodia

NCT07040202•Institut Pasteur du Cambodge

Summary

The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, sepsis, or healthy people. The investigators will perform multiple analyses on the blood samples and compare results between dengue patients and those with sepsis and healthy people.

Detailed Description

This is an observational study enrolling n=200 hospitalized individuals with dengue-like illness, n=30 individuals with sepsis, and n=10 healthy controls to evaluate immune responses in plasma leak syndromes. Sepsis and dengue patients will have blood collected at enrollment, day 1, and day 3, and dengue patients will have an additional blood draw at day 21. Healthy participants will have a single blood draw at enrollment. The blood collected will enable the evaluation of immune kinetics, including changes in neutrophils, cytokines, and adaptive responses, as dengue progresses or improves. Overall, this study will facilitate the evaluation of an understudied cell type and will provide unique data for understanding the temporal changes in the immune response to dengue virus. A better understanding of dengue pathophysiology will help identify potential therapeutic targets to improve outcomes in this disease.

Eligibility

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Patients with dengue-like illness:
•Patients presenting with dengue-like symptoms for a duration of maximum 72h before inclusion. Dengue-like symptoms include: presentation with oral temperature \>38°C AND at least two of the following symptoms suggestive of dengue-like illness: headache, retro-orbital pain, myalgia, joint pain, rash, any bleeding symptoms, nausea or vomiting, lethargy or restlessness , abdominal pain, liver enlargement
•Sepsis patients:
•Patients admitted for less than 48 hours with a primary diagnosis of sepsis as per treating team AND have blood cultures ordered AND on empiric antibiotics due to concern for bacterial infection.
•Healthy controls:
•Participants with no chronic illness, no regular medications, no febrile illness in 28 days, no diagnosis of or treatment for dengue or bacterial infection in the past 6 months.

Exclusion Criteria

•For biobanking purposes, children less than 2 years of age, and individuals who are pregnant, pregnant within the last 90 days, and/or breastfeeding are excluded due to restrictions on the blood volumes and the repeated sampling times.
•Individuals that do not provide informed consent will not be included for the study.
•Severe/chronic/recurrent pathological conditions: clinically significant autoimmune disease or immunodeficiency (including history of organ transplant), haematologic disorders, cardiac diseases, diabetes, cancer, HIV, chronic hepatic or renal insufficiency.
•Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within the 6 months prior to the inclusion. For corticosteroids, this will mean a dose equivalent to 20 mg/day of prednisone or equivalent for \> 2 weeks (inhaled and topical steroids allowed)
•Chronic administration of NSAIDs, including aspirin: prolonged intake (\>2 weeks) within 6 months before study or any intake within the 7 days preceding sampling \[exception for low dose aspirin: maximum 250mg/daily\]
•Any underlying, chronic, or current condition that, in the opinion of the investigator, may interfere with their participation in the study.
•Expected death in the next 48-hours

Locations (3)

Kampong Speu District Referral Hospital

Kampong Speu, Cambodia

International Center of Excellence in Research Cambodia

Phnom Penh, Cambodia

Preah Kossamak Hospital

Phnom Penh, Cambodia

Key Dates

Start Date

June 2, 2025

Primary Completion Date

November 1, 2025

Completion Date

December 1, 2026

Last Updated

June 27, 2025

Enrollment

240

ESTIMATED participants

Conditions

DengueSepsis

Contacts

Chanthap Lon, MD

CONTACT

+855 12976 799 lonc@icercambodia.org

Camila D Odio, MD

CONTACT

camila.odio@nih.gov

Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm

NCT04850456

Critical IllnessSepsis, Severe

View study

RECRUITING

A Multi-Center Data System and Collaborative Network in China for Severe Infection and Sepsis Children

NCT04955210

Critical IllnessSevere Sepsis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 27, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Immune Responses to Dengue and Sepsis

Inclusion Criteria

Exclusion Criteria

Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm

A Multi-Center Data System and Collaborative Network in China for Severe Infection and Sepsis Children

Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit

African Survey on Sepsis Knowledge (ASK)